Preliminary Results

ProtoKinetix Inc., announces today that it has received a report from their new Director of Medical Research in Paris.  Dr. Jean-Marie Dupuis reports that the preliminary results of the third-party evaluation trials on the RECAF™ molecule, being conducted by the Georges Pompidou Hospital are “very positive”.  Jean-Marie states that “the labeling of the malignant cells is strong and clear with a nice delineation between malignant and normal cells.”

Dr. John Todd, president and CEO of ProtoKinetix Inc., is traveling this week to meet with the Department of Pathology at the Georges Pompidou Hospital in Paris to review the results with some of the top medical scientists in Europe.  They will advise Dr. Todd of their plan to complete these trials next month.  Dr. Todd will also be meeting with the members of the ProtoKinetix Scientific Advisory to design the development of antibodies to this receptor site.

About ProtoKinetix:

ProtoKinetix Inc. is a therapeutic development company whose mission is to develop effective biological therapeutics for the treatment of malignancies.  The company is focused on a new generation of monoclonal antibodies termed “Super-antibodies”.  These antibodies are engineered to provide higher potency and resiliency resulting in vastly enhanced therapeutic impact.  ProtoKinetix will use this technology to create therapeutic antibodies to help in the treatment of cancer.

The Private Securities Litigation Reform Act of 1995 provides a “safe harbor” for forward-looking statements.  Some information included in this press release contains statements that are forward-looking.  Such forward-looking information involves significant risks and uncertainties that could affect anticipated results in the future and, accordingly, these results may differ materially from those expressed in any forward-looking statements made by or on behalf of the Company.  For a description of additional risks and uncertainties, please refer to the Company’s filings with the Securities and Exchange Commission.

On behalf of the Board of Directors,
Dr. John Todd, President

Company Office:           
1500-885 West Georgia Street           
Vancouver, BC  V6C 3E8                  

Investor Contact:
BCGU, Business Consulting Group Unlimited
www.bcgu.com
In the U.S. (888) 772-1288
Outside the U.S.: +011 (858) 523-0122